Genetics in Medicine (GIM) is an official journal of the American College of Medical Genetics and Genomics. The journal’s mission is to enhance the knowledge, understanding, and practice of medical genetics and genomics through publications in clinical and laboratory genetics and genomics, including ethical, legal, and social issues as well as public health. As genetics and genomics continue to increase in importance and relevance in medical practice, the journal is an accessible and authoritative resource for the dissemination of medical genetic knowledge to all medical providers through appropriate original research, reviews, commentaries, standards, and guidelines. GIM encourages research that combats racism, includes diverse populations and is written by authors from diverse and underrepresented backgrounds.

Genetics in Medicine
- GIM does not publish case reports
- Manuscripts reporting population level research carried out in predominantly or exclusively White populations will generally not be accepted without strong justification for lack of diversity in the population studied.
- The significance of articles reporting data and/or observations from a limited geographic region is evaluated in the context of whether they are generalizable across relevant populations or whether they might fill a knowledge gap in populations that are underrepresented in genetics research or that experience health disparities.
- Although cancer genetics is a focus, GIM discourages cancer genetics manuscripts with data limited to somatic and/or tumor genetics. Manuscripts with novel findings on non-germline genetics (for example, somatic [tumor] variation, CHIP [clonal hematopoiesis of indeterminate potential], somatic and constitutional mosaicism) that inform our understanding of germline risk may also be considered. Manuscripts reporting on circulating tumor DNA (ctDNA) or “liquid biopsy” are also generally not within the scope of GIM.
- Manuscripts should not contain previously published material without appropriate permission.
- GWAS studies are generally low priority for GIM.
Latest Articles
-
Issue 2949-7744
“It is important to me to know where the information is going”: Views of adults with intellectual disability on data sharing in precision medicine research
-
Issue 2949-7744
12-month outcomes of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) in rare CFTR missense variant
-
Issue 1098-3600
A North Carolina newborn screening pilot for mucopolysaccharidosis II: Evaluating endogenous nonreducing end glycosaminoglycan analysis and IDS sequencing as higher-tier testing options
-
Issue 2949-7744
A population-representative survey on attitudes toward genomic newborn screening in Germany
-
Issue 1098-3600
AAVC: An automated framework for high-accuracy ACMG-based variant classification
-
Issue 2949-7744
ACMG Medical Directors’ Special Interest Group survey: Current challenges for medical genetics clinics
-
Issue 1098-3600
ACMG/AMP variant classification specifications from the ClinGen Epilepsy Sodium Channel Variant Curation Expert Panel
-
Issue 2949-7744
Advocating for professional guidance on medical updates in gamete donation: A perspective from US-based genetic counselors
-
Issue 1098-3600
An economic evaluation of functional genomic testing for individuals with undiagnosed rare disorders
-
Issue 1098-3600
An integrated cardiometabolic genetic testing program in a predominantly Hispanic population within a community setting